Taking stock of COVID-19 vaccines, Pg7

Key Highlights:

• Context: India has seen a mild rise in COVID-19 cases, driven by Omicron sub-variants like LF.1 and NB.1.8.1.

  • The Indian Council of Medical Research (ICMR) and doctors advise against a mass-vaccination drive at present.

  • Over 220 crore doses were administered since January 2021, but current vaccine stocks have expired.

  • WHO and Indian doctors recommend targeted vaccination only for elderly, immunocompromised, and those with comorbidities.

  • India remains prepared to ramp up production if a serious wave or mutation necessitates mass vaccination.

Detailed Insights:

• Most new infections are mild, presenting flu-like symptoms; hospitals report no significant burden.

  • Hybrid immunity (from prior infection + vaccination) has provided widespread protection.

  • The absence of current vaccine stock is due to expiry and low demand; production can resume swiftly if needed.

  • State governments await more epidemiological data before recommending booster policies.

Scientific/Technical Concepts Involved:

• Hybrid Immunity: Combined protection developed through both natural infection and vaccination.

  • Omicron Sub-Variants (e.g., LF.1, NB.1.8.1): Evolved strains with higher transmissibility but reduced severity.

• mRNA vaccine: mRNA vaccines are a type of vaccine that use messenger RNA (mRNA) to instruct cells to produce a specific protein (antigen) from a virus or pathogen.

Mains Mock Question:

Examine the rationale behind India's current COVID-19 vaccination strategy in light of emerging variants and hybrid immunity. How should future pandemic preparedness balance scientific evidence, public perception, and health infrastructure?